Generated: May 27, 2017
|Title:||Delivery system for administration blood-glucose lowering drug|
|Abstract:||A dosage form is disclosed comprising the antidiabetic drug glipizide for administering to a patient in need of glipizide therapy.|
|Inventor(s):||Kuczynski; Anthony L. (Palo Alto, CA), Ayer; Atul D. (Palo Alto, CA), Wong; Patrick S. (Palo Alto, CA)|
|Assignee:||ALZA Corporation (Palo Alto, CA)|
1. A method for stimulating insulin secretion from the beta cells or pancreatic-islet tissue in a patient in need of insulin secretion, wherein the method comprises:
(a) admitting orally into the patient a dosage form comprising:
(1) a wall comprising a member selected from the group consisting of a cellulose ester, cellulose ether and cellulose ester-ether, which will defines:
(2) a lumen;
(3) a first composition in the compartment comprising 1 mg to 100 mg of the drug N-[2-[4-[[[(cyclohexylamino) carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methylpyrazinecarboxamide for stimulating insulin secretion and a pharmaceutically acceptable carrier therefore;
(4) a second composition in the compartment comprising a therapeutically acceptable hydrogel;
(5) an exit passageway in the wall for delivering the first composition from the lumen;
(b) imbibing fluid into the dosage form causing the first composition to provide a dispensable aqueous composition and the second composition to expand and push against the first composition, whereby the first composition is delivered from the dosage form; and,
(c) stimulating insulin secretion by delivering the first composition comprising 1 mg to 100 mg of the drug to the patient.
2. An improvement in a dosage form for administering an antidiabetic drug to a patient, wherein the dosage form comprises:
(a) a wall comprising a member selected from the group consisting of a cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate and cellulose triacetate, which wall defines;
(b) a compartment;
(c) a displacement composition in the compartment comprising a therapeutically acceptable hydrogen that absorbs fluid, expands and pushes a drug composition from the compartment;
(d) an exit passageway in the wall for delivering a drug composition from the compartment; and wherein the improvement comprises:
(e) a drug composition in the compartment, said drug composition comprising 1 mg to 100 mg of substantially aqueous insoluble N-[2-[4-[[[(cyclohexylamino) carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methylpyrazinecarboxamide and a pharmaceutically acceptable carrier therefore, which composition when in the presence of an aqueous fluid that enters the dosage form provides a dispensable aqueous composition that delivers 1 mg to 100 mg of the antidiabetic drug to the patient.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.